Premium
Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony‐stimulating factor and erythropoietin) and high‐dose methylprednisolone
Author(s) -
Imai Yasufumi,
Fukuoka Toshihiko,
Nakatani Atsushi,
Ohsaka Akimichi,
Takahashi Atshushi
Publication year - 1996
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.1996.460997.x
Subject(s) - erythropoietin , medicine , granulocyte colony stimulating factor , hematopoietic growth factor , methylprednisolone , bone marrow , clone (java method) , haematopoiesis , immunology , myelodysplastic syndromes , erythropoiesis , granulocyte , anemia , gastroenterology , endocrinology , stem cell , chemotherapy , biology , genetics , dna
We report a case of hypoplastic myelodyplastic syndrome (MDS) (refractory anemia (RA)) in which sustained trilineage haematological response and persistent disappearance of an abnormal chromosome clone were achieved after treatment with combination therapy of cytokines (granulocyte colony‐stimulating factor (G‐CSF) and erythropoietin (Epo)) and methylprednisolone (mPSL) pulse dose. The patient's haematological recovery was rapid and maintained even after cessation of the therapy. In addition, the predominant chromosome clone 13q− in bone marrow cells disappeared in the fourth week. The patient's improved bone marrow haemopoiesis and disappearance of the abnormal chromosome has continued to the present, 13 months after treatment. The occurrence of both trilineage response and abnormal chromosome disappearance in MDS patients treated with cytokine(s) or steroids in rare. Combination therapy might therefore be advantageous in MDS.